BACKGROUND: Current diagnostic blood tests for prostate cancer (PCa) are unreliable for the early stage disease, resulting in numerous unnecessary prostate biopsies in men with benign disease and false reassurance of negative biopsies in men with PCa. Predicting the risk of PCa is pivotal for making an informed decision on treatment options as the 5-year survival rate in the low-risk group is more than 95% and most men would benefit from surveillance rather than active treatment. Three-dimensional genome architecture and chromosome structures undergo early changes during tumourigenesis both in tumour and in circulating cells and can serve as a disease biomarker. METHODS: In this prospective study we screened whole blood of newly diagnosed, treatment naïve PCa patients (n = 140) and cancer-free controls (n = 96) for the presence of 14,241 chromosomal loops in the loci of 425 genes. RESULTS: We have detected specific chromosome conformation changes in the loci of ETS1, MAP3K14, SLC22A3 and CASP2 genes in peripheral blood from PCa patients yielding PCa detection with 80% sensitivity and 80% specificity. Further analysis between PCa risk groups yielded prognostic validation sets consisting of HSD3B2, VEGFC, APAF1, BMP6, ERG, MSR1, MUC1, ACAT1 and DAPK1 genes that achieved 80% sensitivity and 93% specificity stratifying high-risk category 3 vs low risk category 1 and 84% sensitivity and 89% specificity stratifying high risk category 3 vs intermediate risk category 2 disease. CONCLUSIONS: Our results demonstrate specific chromosome conformations in the blood of PCa patients that allow PCa diagnosis and risk stratification with high sensitivity and specificity.
BACKGROUND: Current diagnostic blood tests for prostate cancer (PCa) are unreliable for the early stage disease, resulting in numerous unnecessary prostate biopsies in men with benign disease and false reassurance of negative biopsies in men with PCa. Predicting the risk of PCa is pivotal for making an informed decision on treatment options as the 5-year survival rate in the low-risk group is more than 95% and most men would benefit from surveillance rather than active treatment. Three-dimensional genome architecture and chromosome structures undergo early changes during tumourigenesis both in tumour and in circulating cells and can serve as a disease biomarker. METHODS: In this prospective study we screened whole blood of newly diagnosed, treatment naïve PCa patients (n = 140) and cancer-free controls (n = 96) for the presence of 14,241 chromosomal loops in the loci of 425 genes. RESULTS: We have detected specific chromosome conformation changes in the loci of ETS1, MAP3K14, SLC22A3 and CASP2 genes in peripheral blood from PCa patients yielding PCa detection with 80% sensitivity and 80% specificity. Further analysis between PCa risk groups yielded prognostic validation sets consisting of HSD3B2, VEGFC, APAF1, BMP6, ERG, MSR1, MUC1, ACAT1 and DAPK1 genes that achieved 80% sensitivity and 93% specificity stratifying high-risk category 3 vs low risk category 1 and 84% sensitivity and 89% specificity stratifying high risk category 3 vs intermediate risk category 2 disease. CONCLUSIONS: Our results demonstrate specific chromosome conformations in the blood of PCa patients that allow PCa diagnosis and risk stratification with high sensitivity and specificity.
Entities:
Keywords:
Blood test; Diagnosis; Epigenetics; Nucleome; Prognosis; Prostate cancer
Authors: Wolfgang A Schulz; Jussi P Elo; Andrea R Florl; Sari Pennanen; Simon Santourlidis; Rainer Engers; Martin Buchardt; Hans-Helge Seifert; Tapio Visakorpi Journal: Genes Chromosomes Cancer Date: 2002-09 Impact factor: 5.006
Authors: Punit Saraon; Dominique Trudel; Ken Kron; Apostolos Dmitromanolakis; John Trachtenberg; Bharati Bapat; Theodorus van der Kwast; Keith A Jarvi; Eleftherios P Diamandis Journal: Prostate Date: 2013-12-06 Impact factor: 4.104
Authors: Carlos López-García; Laurent Sansregret; Enric Domingo; Nicholas McGranahan; Sebastijan Hobor; Nicolai Juul Birkbak; Stuart Horswell; Eva Grönroos; Francesco Favero; Andrew J Rowan; Nicholas Matthews; Sharmin Begum; Benjamin Phillimore; Rebecca Burrell; Dahmane Oukrif; Bradley Spencer-Dene; Michal Kovac; Gordon Stamp; Aengus Stewart; Havard Danielsen; Marco Novelli; Ian Tomlinson; Charles Swanton Journal: Cancer Cell Date: 2017-01-09 Impact factor: 38.585
Authors: Matheus Fabiao de Lima; Mateus de Oliveira Lisboa; Lucas E L Terceiro; Aline Rangel-Pozzo; Sabine Mai Journal: Cells Date: 2022-04-17 Impact factor: 7.666